Smith & Nephew (LON:SN) Downgraded to “Buy” Rating by Citigroup

Smith & Nephew (LON:SN – Get Free Report) was downgraded by analysts at Citigroup to a “buy” rating in a research report issued to clients and investors on Friday,London Stock Exchange reports.

Several other equities research analysts also recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,760 target price on shares of Smith & Nephew in a research report on Thursday, May 21st. UBS Group reaffirmed a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research report on Tuesday, May 5th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,350 price target on shares of Smith & Nephew in a research note on Monday, June 29th. Berenberg Bank reissued a “hold” rating and issued a GBX 13 price objective on shares of Smith & Nephew in a report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,400 price objective on shares of Smith & Nephew in a research note on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,382.62.

Get Smith & Nephew alerts:

Read Our Latest Stock Report on Smith & Nephew

Smith & Nephew Price Performance

SN opened at GBX 1,130.50 on Friday. The firm has a market capitalization of £12.39 billion, a PE ratio of 40.70, a PEG ratio of 0.46 and a beta of 0.68. The company has a 50-day moving average of GBX 1,126.29 and a two-hundred day moving average of GBX 1,204.99. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90.

Smith & Nephew Company Profile

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Recommended Stories

• Five stocks we like better than Smith & Nephew
• Buyer Beware: These 2 Stocks Charts Just Displayed a Death Cross
• PepsiCo’s Dividend Could Turn Patience Into Real Profit
• PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
• Dollar Tree’s Turnaround Is Starting to Take Root

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.